A comparative study of magnetic chitosan (Chi@Fe3O4) and graphene oxide modified magnetic chitosan (Chi@Fe3O4GO) nanocomposites for efficient removal of Cr(VI) from water

© 2019 Elsevier B.V. Magnetic chitosan (Chi@Fe3O4) nanocomposite was synthesized and modified with graphene oxide (Chi@Fe3O4GO) and the potential of both materials as adsorbents was assessed for the removal of chromium (Cr(VI)) from water. The physico-chemical characteristics of magnetic nanocomposites were studied by Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), x-ray diffraction (XRD), Raman spectroscopy and Brunauer–Emmett–Teller (BET). The synthesized adsorbents exhibited varied Cr(VI) removal efficiency at solution pH 2. The reaction kinetics correlated well with the pseudo-second-order model. The maximum adsorption capacity was found to be 142.32 and 100.51 mg g−1 for Chi@Fe3O4 and Chi@Fe3O4GO, respectively. Analysis of thermodynamic parameters suggested that the reaction occurred spontaneously and was endothermic in nature. Reusability studies showed that the adsorbents can be reused for up to four cycles of regeneration. Fixed bed column experiments revealed that the adsorption performance of Chi@Fe3O4 was affected by the flow rate, adsorbent loading and influent metal ion concentration. The results suggest that the prepared adsorbents have the potential to be used in removing Cr(VI) ions from contaminated water

"I am nothing": experiences of loss among women suffering from severe birth injuries in Tanzania

\ud Despite the increased attention on maternal mortality during recent decades, which has resulted in maternal health being defined as a Millennium Development Goal (MDG), the disability and suffering from obstetric fistula remains a neglected issue in global health. Continuous leaking of urine and the physical, emotional and social suffering associated with it, has a profound impact on women's quality of life. This study seeks to explore the physical, cultural and psychological dimensions of living with obstetric fistula, and demonstrate how these experiences shape the identities of women affected by the condition. A cross-sectional study with qualitative and quantitative components was used to explore the experiences of Tanzanian women living with obstetric fistula and those of their husbands. The study was conducted at the Comprehensive Community Based Rehabilitation Tanzania hospital in Dar es Salaam, Bugando Medical Centre in Mwanza, and Mpwapwa district, in Dodoma region. Conveniently selected samples of 16 women were interviewed, and 151 additional women responded to a questionnaire. In addition, 12 women affected by obstetric fistula and six husbands of these affected women participated in a focus group discussions. Data were analysed using content data analysis framework and statistical package for the social sciences (SPSS) version 15 for Microsoft windows. The study revealed a deep sense of loss. Loss of body control, loss of the social roles as women and wives, loss of integration in social life, and loss of dignity and self-worth were located at the core of these experiences. The women living with obstetric fistula experience a deep sense of loss that had negative impact on their identity and quality of life. Acknowledging affected women's real-life experiences is important in order to understand the occurrence and management of obstetric fistula, as well as prospects after treatment. This knowledge will help to improve women's sense of self-worth and maintain their identity as women, wives, friends and community members. Educational programmes to empower women socially and economically and counselling of families of women living with obstetric fistula may help these women receive medical and social support that is necessary.\u

Highly efficient and irreversible removal of cadmium through the formation of a solid solution

Sulfur-containing materials are very attractive for the efficient decontamination of some heavy metals. However, the effective and irreversible removal of Cd2+, coupled with a high uptake efficiency, remains a great challenge due to the relatively low bond dissociation energy of CdS. Herein, we propose a new strategy to overcome this challenge, by the incorporation of Cd2+ into a stable ZnxCd1-xS solid solution, rather than into CdS. This can be realised through the adsorption of Cd2+ by ZnS nanoparticles, which have exhibited a Cd2+ uptake capacity of approximate 400 mg g−1. Through this adsorption mechanism, the Cd2+ concentration in a contaminated solution could effectively be reduced from 50 ppb to 80% uptake capacity for Cd2+, compared with only 9% uptake capacity for similarly-aged FeS particles. This work reveals a new mechanism for Cd2+ removal with ZnS and establishes a valuable starting point for further studies into the formation of solid solutions for hazardous heavy metal removal applications

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Modified biochar from Moringa seed powder for the removal of diclofenac from aqueous solution

© 2019, The Author(s). In this study, Moringa seed powder (MSP) was pyrolyzed at 450 °C to synthesize Moringa seed powder biochar (MSPB) and treated with phosphoric acid (H3PO4) to synthesize phosphate-modified Moringa seed powder biochar (MSPB-HPO) as an adsorbent for the removal of diclofenac (Dfc) from aqueous solution. Fourier transform infrared (FTIR) analysis, energy dispersive X-ray spectroscopy (EDS), scanning electron microscopy (SEM), and pH point of zero charge (pHpzc) were conducted to give more insight into the adsorbent’s properties. The SEM analysis showed the transformations in the surface morphology from the parent material to the synthesized materials after the thermal and acid treatment. EDS analysis revealed the variation in the elemental composition of the materials prior to and after adsorption of Dfc ions. The FTIR analysis showed changes and peak intensities of functional groups involved in Dfc removal. The pHpzc showed the charge carried by MSPB-HPO in different pH conditions. Isotherm data best matched the Sips model, and the pseudo-second-order model best described the adsorption kinetics. The maximum adsorption capacity of MSPB-HPO by Sips model was found to be 100.876 mg g−1

Mineralization of Farm Manures and Slurries under Aerobic and Anaerobic Conditions for Subsequent Release of Phosphorus and Sulphur in Soil

A good understanding of nutrient release from manure or compost after application through mineralization is important to assure meeting the nutrient demand of crops, to secure timely fertilizer application and to enhance nutrient use efficiency. The current study was done to evaluate phosphorus (P) and sulphur (S) release patterns from different types of manures viz. cow dung, cow dung slurry, tricho-compost, vermicompost, poultry manure, poultry manure slurry and mungbean residues. The mineralization study was performed under aerobic (field capacity) and anaerobic (waterlogging) conditions for 180 days at 25 ± 1 °C in the laboratory. The release of P and S showed the highest values within 75–180 and 75–150 days, respectively, and was always higher in aerobic conditions than in anaerobic conditions. The first-order kinetic cumulative model was a good fit for mineralization, which was significantly influenced by manure type, soil moisture level and incubation period. Poultry manure slurry exerted the highest P and S release under both moisture conditions. Both slurries showed higher potential mineralization, with a lower rate constant for these elements compared to that in their manure states. Hence, appropriate manures should be chosen and applied in the proper quantity to provide exact amounts of nutrients, to increase crops nutrient use efficiency and to formulate correct fertilizer recommendations